Problémamegoldó ápolási-gondozási modell                     Parkinson-kórban

Csóka, Mária; Molnár, Sándorné; Kellős, Éva; Domján, Gyula

doi:10.1556/650.2016.30479

Cited by 3 publications

(1 citation statement)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A Pax Corporis a betegségekről, azok okairól és kezelésükről szóló első részletes magyar nyelvű összefoglaló könyv. Pápai [14] Ideggyógyászati Szemle 2013 Kovács [15] Lege Artis Medicinae (LAM) 2014 Faludi és mtsai [16] Orvosi Hetilap 2015 Csóka és mtsai [17] Orvosi…”

Section: Kivonatunclassified

International recognition of Ferenc Pápai Páriz as one of the first descriptors of all 4 cardinal signs of Parkinson’s disease

Bereczki

Árpád²,

Benedek

et al. 2018

Bulletin of Medical Sciences

View full text Add to dashboard Cite

Pax Corporis is the first book written in Hungarian that presents in detail human diseases, their etiology and treatment. Ferenc Pápai Páriz had completed the manuscript entitled Pax Corporis in 1687, and it was published 3 years later in 1690 in Kolozsvár. Ferenc Pápai Páriz summarized the knowledge he gained during his studies and accumulated during his personal practice. He did not write this book for the professionals but for those poor people who had no access to physician’s care. This was the reason why Pax Corporis was written in Hungarian. Whereas Pápai’s Latin language scripts – for example his doctoral thesis written in Basel – are known to the international scientific community, the Hungarian language Pax Corporis remained unknown for all who were not familiar with the language. For this reason it also remained neglected that in Pax Corporis Ferenc Pápai Páriz had given a detailed description of all four currently acknowledged cardinal signs of Parkinson’s disease – tremor, rigor, bradykinesia and postural instability – and also of other characteristics of the disease 130 years before James Parkinson. The report on the description of the syndrome of Parkinson’s disease in Pax Corporis was presented to the international professional community in 2009. In the current study we evaluated the international recognition of Ferenc Pápai Páriz as one of the first descriptors of all 4 cardinal signs of Parkinson’s disease. We searched scientific citation databases – Web of Science, Scopus, Google Scholar – and also performed general searches on the web. We found that until April 2018 Pápai Páriz has been cited among those who first described the complete motor syndrome of Parkinson’ disease in Pax Corporis, in many countries of the world from New Zealand to Canada, and also in 16 European countries. Citations appeared in dissertations, scientific publications, textbooks, handbooks, professional websites and other documents. Three centuries after his original Hungarian script, Ferenc Pápai Páriz got his international recognition in medical history as one of the first descriptors of the syndrome of Parkinson’s disease.

show abstract

Section: Kivonatunclassified

International recognition of Ferenc Pápai Páriz as one of the first descriptors of all 4 cardinal signs of Parkinson’s disease

Bereczki

Árpád²,

Benedek

et al. 2018

Bulletin of Medical Sciences

View full text Add to dashboard Cite

show abstract

A szelektív monoaminoxidáz-B-gátlók helye a Parkinson-kór kezelési stratégiájában a marosvásárhelyi ideggyógyászati klinikák gyakorlatában

Szász

Constantin²,

Fazakas

et al. 2017

Orvosi Hetilap

View full text Add to dashboard Cite

show abstract

<p>Profile Of Patients With Advanced Parkinson’s disease Suitable For Device-Aided Therapies: Restrospective Data Of A Large Cohort Of Romanian Patients</p>

Szász

Constantin²,

Orbán-Kis

et al. 2019

NDT

View full text Add to dashboard Cite

Background: There is insufficient data in the literature regarding the real-life, daily clinical practice evaluation of patients with advanced Parkinson's disease (APD). We are not sure what is the upper limit of dopaminergic medication, especially the levodopa (LD) dosage, and how it is influenced by access and suitability to the various add-on and device-aided therapies (DAT). Objective: This retrospective study explored the profile of APD patients that were considered and systematically evaluated regarding the suitability for DAT. Methods: We analyzed the data from 311 consecutive patients with APD hospitalized between 2011 and 2017 that 1) described at least 2 hrs/day off periods divided into at least two instances/day (except early morning akinesia), 2) were in stage 3 or above on the Hoehn and Yahr scale, 3) were with or without dyskinesia, and 4) received at least four levodopa doses/day combined with adjuvant therapy. Results: Of the 311 patients enrolled initially, 286 patients showed up for the second visit, of which in 125 cases we assessed that DAT would be necessary. Finally, 107 patients were tested in our clinic to confirm the efficacy of LCIG. Patients selected for DAT had significantly longer off periods, more frequent dyskinesia, early morning akinesia, and freezing despite having significantly higher LD doses than those with an improved conservative therapy. Conclusion: Patients with APD can have a variety of symptoms, and because symptoms and therapeutical efficacy can be manifested in many different combinations, it is not possible to decide using a single, rigid set of criteria which APD patient is eligible for DAT. Nevertheless, treating physicians should refer APD patients to a specialized movement disorder center when patients with an average daily dose of LD of at least 750-1000 mg and maximal complementary therapies present daily motor complications that significantly reduce the quality of life.

show abstract

Problémamegoldó ápolási-gondozási modell Parkinson-kórban

Cited by 3 publications

References 2 publications

International recognition of Ferenc Pápai Páriz as one of the first descriptors of all 4 cardinal signs of Parkinson’s disease

International recognition of Ferenc Pápai Páriz as one of the first descriptors of all 4 cardinal signs of Parkinson’s disease

A szelektív monoaminoxidáz-B-gátlók helye a Parkinson-kór kezelési stratégiájában a marosvásárhelyi ideggyógyászati klinikák gyakorlatában

<p>Profile Of Patients With Advanced Parkinson’s disease Suitable For Device-Aided Therapies: Restrospective Data Of A Large Cohort Of Romanian Patients</p>

Contact Info

Product

Resources

About